Related Experiment Videos
Prognostic significance of complement alleles Bf and C4 in early rheumatoid arthritis
L Paimela1, M Leirisalo-Repo, M L Lokki
1Department of Rheumatology, Helsinki City Hospital, Finland.
Insights
The C4B null allele in rheumatoid arthritis (RA) patients indicates a more severe disease course and increased risk of treatment side effects. This finding suggests C4B null allele may identify a specific RA subgroup needing closer monitoring.
Area of Science:
- Immunogenetics
- Rheumatology
- Complement System
Background:
- Major histocompatibility complex (MHC) class III complement components play roles in immune regulation.
- Factor B (Bf), C4A, and C4B are key complement factors influencing inflammatory processes.
- Understanding their role in rheumatoid arthritis (RA) is crucial for disease management.
Purpose of the Study:
- To investigate the prognostic significance of complement components Bf, C4A, and C4B in early rheumatoid arthritis (RA).
- To determine if specific alleles of these complement components correlate with disease activity, progression, or treatment outcomes.
Main Methods:
- A 3-year prospective study involving 73 patients diagnosed with early RA.
- Analysis of disease activity, radiological progression, and side effects of antirheumatic treatment.
- Genotyping for Bf, C4A, and C4B alleles, focusing on null alleles.
Main Results:
- Patients with the C4B null allele exhibited higher disease activity and greater radiological progression compared to those with C4A null or no null alleles.
- The C4B null allele was associated with an increased susceptibility to side effects from antirheumatic therapies.
- No significant association was found between Bf phenotypes and RA severity.
Conclusions:
- The C4B null allele demonstrates prognostic significance in early RA.
- It may identify a distinct subgroup of RA patients characterized by a more complicated disease course and higher risk of adverse treatment effects.
- Further research is warranted to explore therapeutic strategies for this subgroup.
Abstract:
The prognostic significance of class III major histocompatibility complex complement components, factor B (Bf), C4A and C4B, were studied in a 3-year prospective study of 73 patients with early RA. Patients with C4B null allele had higher disease activity with more radiological progression than patients with C4A null allele or patients without null allele. C4B null allele also associated with increased susceptibility to side effects from antirheumatic treatment. The Bf phenotypes did not associate with the severity of RA. C4B null allele may have prognostic significance in determining a special subgroup of RA patients with a more complicated course of the disease.